AxoGen (AXGN) Initiates BLA Submission for Avance Nerve Graft
- AxoGen (AXGN) starts the process of BLA submission to the FDA for the approval of its Avance Nerve Graft.
- 05/17/2024
|
AxoGen, Inc. (AXGN) Q1 2024 Earnings Call Transcript
- AxoGen, Inc. (NASDAQ:AXGN ) Q1 2024 Earnings Conference Call May 2, 2024 8:00 AM ET Company Participants Harold Tamayo - VP, Finance and IR Karen Zaderej - Chairman, CEO and President Nir Naor - CFO Conference Call Participants Michael Sarcone - Jefferies Mike Kratky - Leerink Partners Caitlin Cronin - Canaccord Genuity Ross Osborn - Cantor Fitzgerald Operator Greetings, and welcome to the AxoGen, Inc. 2024 First Quarter Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.
- 05/05/2024
|
AxoGen (AXGN) Reports Q1 Loss, Lags Revenue Estimates
- AxoGen (AXGN) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.10 per share a year ago.
- 05/02/2024
|
Axogen, Inc Reports First Quarter 2024 Financial Results
- ALACHUA, Fla. and TAMPA, Fla., May 02, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31, 2024.
- 05/02/2024
|
Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™
- ALACHUA, Fla. and TAMPA, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announces the first surgical implantations of its newest product, Avive+ Soft Tissue Matrix™.
- 04/29/2024
|
Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
- ALACHUA, Fla. and TAMPA, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report first quarter 2024 financial results on Thursday, May 2, 2024, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release.
- 04/16/2024
|
AxoGen, Inc. (AXGN) Q4 2023 Earnings Call Transcript
- AxoGen, Inc. (NASDAQ:AXGN ) Q4 2023 Earnings Call Transcript March 5, 2024 8:00 AM ET Company Participants Harold Tamayo - VP, Finance and IR Karen Zaderej - Chairman, CEO and President Nir Naor - CFO Conference Call Participants Chris Pasquale - Nephron Mike Sarcone - Jefferies Mike Kratky - Leerink Partners Caitlin Cronin - Canaccord Genuity Dave Turkaly - Citizens JMP Ross Osborn - Cantor Fitzgerald Operator Hello, and welcome to the AxoGen, Inc. 2023 Fourth Quarter and Full Year Financial Results Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded.
- 03/05/2024
|
Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results
- ALACHUA, Fla. and TAMPA, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2023.
- 03/05/2024
|
4 Must-Buy Stocks for Remarkable Earnings Acceleration
- Some of the notable companies to have witnessed solid earnings acceleration as of now are Protagonist Therapeutics (PTGX), AxoGen (AXGN), Western Digital (WDC) and Phunware (PHUN).
- 03/04/2024
|
AxoGen (AXGN) Is a Great Choice for 'Trend' Investors, Here's Why
- AxoGen (AXGN) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
- 02/28/2024
|
AxoGen, Inc. (AXGN) Hit a 52 Week High, Can the Run Continue?
- AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
- 02/26/2024
|
3 Best Stocks to Buy for Remarkable Earnings Acceleration
- Invest in stocks such as AxoGen (AXGN), Western Digital (WDC) and Gen Digital (GEN) as of now for superb earnings acceleration.
- 02/16/2024
|
Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024
- ALACHUA, Fla. and TAMPA, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report 2023 fourth quarter and full-year financial results on Tuesday, March 5, 2024, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release.
- 02/13/2024
|
Here's Why Momentum in AxoGen (AXGN) Should Keep going
- If you are looking for stocks that are well positioned to maintain their recent uptrend, AxoGen (AXGN) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
- 02/12/2024
|
Is AxoGen (AXGN) Stock Outpacing Its Medical Peers This Year?
- Here is how AxoGen (AXGN) and Boston Scientific (BSX) have performed compared to their sector so far this year.
- 02/06/2024
|
Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- ALACHUA, Fla. and TAMPA, Fla., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced making Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) in connection with the employment and appointment of John Manning to the position of Area Vice President of Sales. Mr. Manning will report to Doris Quackenbush, Vice President of Sales.
- 02/02/2024
|
4 Top Stocks That Flaunt Solid Earnings Acceleration
- Invest in stocks such as AxoGen (AXGN), Western Digital (WDC), Accolade (ACCD) and Credo Technology (CRDO) for superb earnings acceleration.
- 01/29/2024
|
Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap
- REPOSE® met its primary endpoint of non-inferiority between the pain visual analog scale outcomes for neurectomy with Axoguard Nerve Cap® vs. standard-of-care neurectomy at Month 12.
- 01/18/2024
|
3 Stocks Worth a Look for Solid Earnings Acceleration
- Keep a tab on stocks such as Aspen Aerogels (ASPN), AxoGen (AXGN) and Credo Technology Group (CRDO) for superb earnings acceleration.
- 01/11/2024
|
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023
- ALACHUA, Fla. and TAMPA, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced preliminary unaudited fourth quarter and full-year 2023 revenue.
- 01/04/2024
|
Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025
- ALACHUA and TAMPA, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that President and Chief Executive Officer (CEO) Karen Zaderej plans to retire from the Company by January 2025. The Company's Board of Directors will retain an executive recruitment firm to manage a search for her successor. When a new CEO is in place, Ms. Zaderej will step down from her executive post and Board duties and continue as a consultant to Axogen for an additional nine months to support the leadership transition and the submission process of the Biologics License Application (BLA) for Avance® Nerve Graft. While the transition is planned to be no later than Jan. 5, 2025, it could occur sooner depending on the timing of a new CEO appointment.
- 01/04/2024
|
Axogen, Inc. to Report Third Quarter 2023 Financial Results and Host Conference Call on November 7, 2023
- ALACHUA, Fla. and TAMPA, Fla., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report third quarter 2023 financial results on Tuesday, November 7, 2023 before the market opens. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release.
- 10/18/2023
|
AxoGen (AXGN) Moves 6.8% Higher: Will This Strength Last?
- AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 09/28/2023
|
Axogen to Participate at Upcoming Investor Conferences
- ALACHUA and TAMPA, Fla., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, Chairman, Chief Executive Officer, and President, will participate in two investor conferences in September.
- 08/31/2023
|
AxoGen, Inc. (AXGN) Q2 2023 Earnings Call Transcript
- AxoGen, Inc. (NASDAQ:AXGN ) Q2 2023 Earnings Conference Call August 7, 2023 4:30 PM ET Company Participants Adanna Alexander - Investor Relations Consultant Karen Zaderej - Chairman, Chief Executive Officer and President Pete Mariani - Executive Vice President and Chief Financial Officer Conference Call Participants Michael Sarcone - Jefferies Dave Turkaly - JMP Securities Ross Osborn - Cantor Fitzgerald Caitlin Cronin - Canaccord Genuity Chris Pasquale - Nephron Research Operator Greetings. Welcome to the AxoGen, Inc. Reports Second Quarter 2023 Financial Results Conference Call.
- 08/07/2023
|
AxoGen (AXGN) Reports Q2 Loss, Lags Revenue Estimates
- AxoGen (AXGN) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.06 per share a year ago.
- 08/07/2023
|
Axogen, Inc. to report second quarter 2023 financial results and host conference call on August 7, 2023
- ALACHUA, Fla. and TAMPA, Fla., July 26, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report second quarter 2023 financial results on Monday, August 7, 2023 after the market closes. Axogen management will host an investment-community conference call and webcast at 4:30 p.m. ET following the release.
- 07/26/2023
|
AxoGen: Far More Constructive With Q1 Numbers, Profitability The Next Hurdle
- AxoGen is showing potential for growth, and management expects a record $160 million in revenue this year. Focus on core and active accounts has yielded positive results, with YoY growth of 23% and 9% respectively. However, the lack of earnings and catalysts makes it challenging to estimate an accurate valuation, warranting a hold rating for now.
- 06/23/2023
|
Wall Street Analysts Think AxoGen (AXGN) Could Surge 69.62%: Read This Before Placing a Bet
- The mean of analysts' price targets for AxoGen (AXGN) points to a 69.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- 06/09/2023
|
Axogen, Inc. to report first quarter 2023 financial results and host conference call on May 9, 2023
- ALACHUA, Fla. and TAMPA, Fla., April 18, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report first quarter 2023 financial results on Tuesday, May 9, 2023 before the market opens. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release.
- 04/18/2023
|
Axogen, Inc. to report fourth quarter 2022 financial results and host conference call on March 14, 2023
- ALACHUA, Fla. and TAMPA, Fla., March 02, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report fourth quarter 2022 financial results on Tuesday, March 14, 2023 before the market opens. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release.
- 03/02/2023
|
Here's Why "Trend" Investors Would Love Betting on AxoGen (AXGN)
- If you are looking for stocks that are well positioned to maintain their recent uptrend, AxoGen (AXGN) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
- 11/11/2022
|
AxoGen, Inc. (AXGN) Q3 2022 Earnings Call Transcript
- AxoGen, Inc. (NASDAQ:AXGN ) Q3 2022 Earnings Conference Call November 8, 2022 8:00 AM ET Company Participants Ed Joyce - Director, IR Karen Zaderej - Chairman, CEO & President Pete Mariani - EVP & CFO Conference Call Participants Mike Sarcone - Jefferies Chris Pasquale - Nephron Ryan Zimmerman - BTIG Kyle Rose - Canaccord Genuity Ross Osborn - Cantor Fitzgerald Dave Turkaly - JMP Operator Welcome to the AxoGen Third Quarter 2022 Conference Call. At this time, all participants are in a listen-only mode.
- 11/08/2022
|
AxoGen (AXGN) Reports Q3 Loss, Tops Revenue Estimates
- AxoGen (AXGN) delivered earnings and revenue surprises of 93.33% and 2.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/08/2022
|
Axogen to Participate at Upcoming Investor Conferences
- ALACHUA, Fla. and TAMPA, Fla., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, chairman, CEO, and president, and Peter Mariani, executive vice president and CFO will participate in upcoming investor conferences in November and December.
- 11/03/2022
|
AxoGen (AXGN) Upgraded to Buy: Here's What You Should Know
- AxoGen (AXGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 10/27/2022
|
Axogen, Inc. to report third quarter 2022 financial results and host conference call on November 8, 2022
- ALACHUA and TAMPA, Fla., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report third quarter 2022 financial results on Tuesday, November 8, 2022 before the market opens. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release.
- 10/20/2022
|
AxoGen (AXGN) Soars 8.6%: Is Further Upside Left in the Stock?
- AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 09/29/2022
|
AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q2 2022 Results - Earnings Call Transcript
- AxoGen, Inc. (NASDAQ:AXGN ) Q2 2022 Results Conference Call August 3, 2022 4:30 PM ET Company Participants Ed Joyce - Director, IR Karen Zaderej - Chairman, President & CEO Peter Mariani - EVP & CFO Conference Call Participants Operator Welcome to the AxoGen Second Quarter 2022 Conference Call. At this time, all participants are in a listen-only mode.
- 08/06/2022
|
AxoGen (AXGN) Reports Q2 Loss, Tops Revenue Estimates
- AxoGen (AXGN) delivered earnings and revenue surprises of 60% and 5.04%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/03/2022
|
AxoGen: Investors Are Positioned Long Leading Into Q2 FY22 Earnings
- AxoGen is set to report Q2 FY22 earnings on Wednesday, following a period of flat performance on the chart. The company released top-line forecasts in its earnings pre-release from July, implying a period of growth.
- 08/02/2022
|
Axogen, Inc. to present at Canaccord Genuity's 42nd Annual Growth Conference
- ALACHUA. Fla. and TAMPA, Fla, July 29, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, chairman, CEO, and president, will present at Canaccord Genuity's 42nd Annual Growth Conference in Boston. The presentation is scheduled for Wednesday, August 10, 2022, at 12:30 p.m. ET.
- 07/29/2022
|
AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q1 2022 Results - Earnings Call Transcript
- AxoGen, Inc. (NASDAQ:AXGN ) Q1 2022 Results Conference Call May 4, 2022 4:30 PM ET Company Participants Ed Joyce - Director, IR Karen Zaderej - Chairman, President & CEO Peter Mariani - EVP & CFO Erick DeVinney - VP of Peripheral Nerve Science & Clinical Innovation Conference Call Participants Erin Fahey - SVB Leerink Frank Pinal - Jefferies Ross Osborn - Cantor Fitzgerald Dave Turkaly - JMP Securities Operator Good day, ladies and gentlemen, and welcome to the AxoGen, Inc. Reports First Quarter Earnings Call. [Operator Instructions] At this time, it is my pleasure to turn the floor over to your host, Ed Joyce.
- 05/07/2022
|
Axogen Aces Phase 3 Study For Avance Nerve Graft
- Axogen Inc (NASDAQ: AXGN) announced topline results from its RECON Clinical Study comparing Avance Nerve Graft to conduits in digital nerve injuries. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral.
- 05/05/2022
|
Axogen, Inc. to Report First Quarter 2022 Financial Results and Host Conference Call on May 4, 2022
- ALACHUA, Fla. and TAMPA, Fla., April 13, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report first quarter 2022 financial results on Wednesday, May 4, 2022 after the market closes. Axogen management will host an investment-community conference call and webcast following the release at 4:30 p.m. ET.
- 04/13/2022
|
Axogen Needs RECON More Than Ever To Recharge The Bull Case
- Axogen reported disappointing fourth quarter results, with procedure volume down 8% on issues related to COVID-19 and hospital staffing.
- 03/08/2022
|
AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q4 2021 Results - Earnings Call Transcript
- AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q4 2021 Results - Earnings Call Transcript
- 02/22/2022
|
AxoGen (AXGN) Reports Q4 Loss, Tops Revenue Estimates
- AxoGen (AXGN) delivered earnings and revenue surprises of 38.46% and 0.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 02/22/2022
|
Earnings Preview: AxoGen (AXGN) Q4 Earnings Expected to Decline
- AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/15/2022
|
Axogen to Participate at Upcoming Investor Conferences
- ALACHUA, Fla. and TAMPA, Fla., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced it will participate in two investor conferences in February.
- 02/03/2022
|
Axogen, Inc. to Report Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call on February 22, 2022
- ALACHUA, Fla. and TAMPA, Fla., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report fourth quarter and full-year 2021 financial results on Tuesday, February 22, 2022 after the market closes. Axogen management will host an investment-community conference call and webcast following the release at 4:30 p.m. ET.
- 02/02/2022
|
AxoGen's (AXGN) CEO Karen Zaderej on Q3 2021 Results - Earnings Call Transcript
- AxoGen's (AXGN) CEO Karen Zaderej on Q3 2021 Results - Earnings Call Transcript
- 11/03/2021
|
AxoGen (AXGN) Reports Q3 Loss, Misses Revenue Estimates
- AxoGen (AXGN) delivered earnings and revenue surprises of 25.00% and -9.95%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 11/03/2021
|
Axogen: Q3 Earnings Insights
- Axogen (NASDAQ:AXGN) reported its Q3 earnings results on Wednesday, November 3, 2021 at 04:00 PM. Here's what investors need to know about the announcement.
- 11/03/2021
|
Axogen, Inc. to Report Third Quarter Financial Results and Host Conference Call on November 3, 2021
- ALACHUA, Fla. and TAMPA, Fla., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report third quarter 2021 financial results on Wednesday, November 3, 2021 after the market closes. Axogen management will host an investment-community conference call and webcast following the release at 4:30 p.m. ET.
- 10/13/2021
|
Axogen RECON(SM) Clinical Study Completes Subject Follow-up
- RECON is a pivotal study supporting the Company's Biologics License Application (BLA) for Avance® Nerve Graft RECON is a pivotal study supporting the Company's Biologics License Application (BLA) for Avance® Nerve Graft
- 09/01/2021
|
Axogen: Renewed Covid-19 Worries Hitting, But The Growth Story Is Very Appealing
- Axogen continues posting double-digit growth in volumes against 2019 levels despite trauma, breast recon, and oral-maxillofacial procedures still well below pre-pandemic levels.
- 08/25/2021
|
AxoGen's (AXGN) CEO Karen Zaderej on Q2 2021 Results - Earnings Call Transcript
- AxoGen's (AXGN) CEO Karen Zaderej on Q2 2021 Results - Earnings Call Transcript
- 08/05/2021
|
AxoGen (AXGN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
- AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/28/2021
|
Axogen, Inc. Appoints John H. Johnson to Board of Directors
- Global leader brings 30+ years of biopharma experience to Axogen, Inc. Board of Directors Global leader brings 30+ years of biopharma experience to Axogen, Inc. Board of Directors
- 07/19/2021
|
Axogen, Inc. to Report Second Quarter Financial Results and Host Conference Call on August 4, 2021
- ALACHUA, Fla. and TAMPA, Fla., July 14, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report second quarter 2021 financial results on Wednesday, August 4, 2021 after the market closes. Axogen management will host an investment-community conference call and webcast following the release at 4:30 p.m. ET.
- 07/14/2021
|
Axogen, Inc. to present at the Jefferies Virtual Healthcare Conference and the JMP Securities Life Sciences Conference
- ALACHUA, Fla. and TAMPA, Fla., May 18, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president and Peter J. Mariani, executive vice president and CFO will present at two upcoming investor conferences.
- 05/18/2021
|
AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q1 2021 Results - Earnings Call Transcript
- AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q1 2021 Results - Earnings Call Transcript
- 05/09/2021
|
AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates
- AxoGen (AXGN) delivered earnings and revenue surprises of 52.94% and 8.33%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 05/05/2021
|
Recap: Axogen Q1 Earnings
- Shares of Axogen (NASDAQ:AXGN) moved higher in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 57.89% over the past year to ($0.08), which beat the estimate of ($0.16).
- 05/05/2021
|
Recovering Trauma Cases Should Highlight AxoGen's Improving Execution
- AxoGen has reported two consecutive quarters of double-digit growth despite lower trauma presentations during the pandemic and restrictions on marketing/training efforts. Clinical data continue to support the company's key products, with patients experience reduced pain/improved sensation in trauma, breast recon, and post-surgical pain.
- 03/11/2021
|
Axogen, Inc. Promotes Peter J. Mariani to Executive Vice President and Chief Financial Officer
- ALACHUA, Fla., March 01, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the promotion of Peter J. Mariani to Executive Vice President and Chief Financial Officer.
- 03/01/2021
|
AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q4 2020 Results - Earnings Call Transcript
- AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q4 2020 Results - Earnings Call Transcript
- 02/22/2021
|
Axogen, Inc. Reports 2020 Fourth Quarter and Full-Year Financial Results
- ALACHUA, Fla., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2020.
- 02/22/2021
|
Axogen, Inc. to Participate at Upcoming February Investor Conferences
- ALACHUA, Fla., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced it will participate in two investor conferences in February.
- 02/04/2021
|
A Trio of Fast Growing Revenue Stock Picks
- The S&P 500 stocks saw their aggregate trailing 12-month real revenue per share rise at a compound average growth rate (CAGR) of nearly 2% per annum over the past five years. The share price of the benchmark index for the U.S. stock market closed at $3,824.68 on Friday, up by nearly 100% over the past five years through Jan. 8.
- 01/11/2021
|
Axogen to Participate at AAHS ASPN ASRM 2021 Virtual Annual Meetings
- Clinical evidence supporting the company's platform for nerve repair will be featured in several presentations during the scientific sessions Clinical evidence supporting the company's platform for nerve repair will be featured in several presentations during the scientific sessions
- 01/05/2021
|
Axogen Sponsors Donate Life at 2021 Virtual Rose Parade Celebration
- ALACHUA, Fla., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, announced today their sponsorship of Donate Life at the annual Tournament of Roses® celebration. For 2021, the Rose Parade will be held as a televised special in Pasadena, CA on New Year's Day.
- 12/23/2020
|
AxoGen: Operating Efficiencies Come Through The P&L And Cash-flow Statement
- AxoGen: Operating Efficiencies Come Through The P&L And Cash-flow Statement
- 12/20/2020
|
Axogen, Inc. to Participate at Jefferies Virtual London Healthcare Conference and Canaccord Genuity Virtual MedTech & Diagnostics Forum
- ALACHUA, Fla., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president, will present at two upcoming investor events – the Jefferies Virtual London Healthcare Conference and the Canaccord Genuity Virtual MedTech & Diagnostics Forum.
- 11/04/2020
|
Axogen, Inc. Reports Third Quarter 2020 Financial Results
- ALACHUA, Fla., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the second quarter ended September 30, 2020.
- 10/29/2020
|
AxoGen (NASDAQ:AXGN) Stock Rating Upgraded by BidaskClub
- AxoGen (NASDAQ:AXGN) was upgraded by equities research analysts at BidaskClub from a “sell” rating to a “hold” rating in a report issued on Friday, BidAskClub reports. Several other research analysts have also commented on AXGN. BTIG Research reissued a “hold” rating on shares of AxoGen in a research report on Wednesday, August 5th. Canaccord Genuity […]
- 10/18/2020
|
AxoGen (AXGN) Receives a Hold from Canaccord Genuity - Markets
- Canaccord Genuity analyst Kyle Rose maintained a Hold rating on AxoGen (AXGN – Research Report) on October 11 and set
- 10/13/2020
|
AxoGen Struggling Through A Protracted Restructuring (NASDAQ:AXGN)
- COVID-19 has complicated a sales restructuring effort that was already severely testing the patience of investors, as the company looks to refocus on its core trauma opportunity.
- 10/02/2020
|
Axogen, Inc. Appoints Paul G. Thomas to Board of Directors
- ALACHUA, Fla., Sep 30, 2020 (GLOBE NEWSWIRE via COMTEX) --
Healthcare veteran brings 30+ years of medtech experience to Axogen, Inc. Board of Directors...
- 09/30/2020
|
Axogen, Inc. Appoints Paul G. Thomas to Board of Directors
- ALACHUA, Fla., Sep 30, 2020 (GLOBE NEWSWIRE via COMTEX) -- Healthcare veteran brings 30+ years of medtech experience to Axogen, Inc. Board of Directors...
- 09/30/2020
|
Jacobs Levy Equity Management Inc. Purchases New Stake in AxoGen, Inc (NASDAQ:AXGN)
- Jacobs Levy Equity Management Inc. acquired a new position in AxoGen, Inc (NASDAQ:AXGN) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 57,956 shares of the medical equipment provider’s stock, valued at approximately $536,000. Jacobs Levy Equity Management Inc. owned 0.14% of AxoGen as […]
- 09/21/2020
|
Is AxoGen's (NASDAQ:AXGN) 219% Share Price Increase Well Justified?
- When you buy a stock there is always a possibility that it could drop 100%. But when you pick a company that is really...
- 08/07/2020
|
AxoGen (AXGN) Reports Q2 Loss, Tops Revenue Estimates
- AxoGen (AXGN) delivered earnings and revenue surprises of 40.00% and 5.31%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- 08/05/2020
|
Axogen, Inc. Reports Second Quarter 2020 Financial Results
- ALACHUA, Fla., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the second quarter ended June 30, 2020. Second Quarter 2020 Financial Results and Recent Business Highlights * Net revenue was $22.1 million during the quarter, a decrease of 17% compared to second quarter 2019 revenue of $26.7 million. * Gross margin was 74.7% for the quarter, compared to 84.1% in the second quarter of 2019. * Net loss was $8.1 million for the quarter, or $0.20 per share, compared to a net loss of $7.0 million, or $0.18 per share, in the second quarter of 2019. * Adjusted net loss was $5.9 million for the quarter, or $0.15 per share, compared with adjusted net loss of $3.7 million, or $0.10 per share, in the second quarter of 2019. * Adjusted EBITDA loss was $5.7 million for the quarter, compared to an adjusted EBITDA loss of $4.1 million in the second quarter of 2019. * On June 30, 2020 the Company announced a new seven-year, interest-only financing agreement with Oberland Capital, which provides up to $75.0 million in total financing commitments, with $35 million drawn at the close. * The balance of cash, cash equivalents, and investments on June 30, 2020 was $109.9 million, compared to a balance of $89.0 million on March 31, 2020. The net change reflects the receipt of net debt proceeds of $34.7 million, partially offset by capital expenditures in the quarter of $7.8 million and net operating cash burn of $6.0 million. * On July 22, 2020 the Company reported that its RECONSM Clinical Study had completed target enrollment of 220 subjects.“We are encouraged by the performance of our commercial team and the demand for our products over the course of the quarter as surgery schedules opened and hospitals quickly moved to complete nerve repair procedures,” commented Karen Zaderej, chairman, CEO, and president of Axogen. “We expect that most deferred nerve repair procedures will be scheduled by the end of the summer and believe that regional COVID-19 resurgence may continue to negatively impact the incidence of trauma and surgical procedure volumes in certain geographies. As a result, we remain measured in our outlook for the remainder of the year and expect that revenue in the third and fourth quarters will continue to trend below prior-year results. However, we are pleased with the resilience we have seen with our business and we believe that the strength of our balance sheet, along with our cost mitigation initiatives, will allow us to emerge from this pandemic-related downturn as a stronger, leaner organization on a path to profitability.”Additional Operational and Business Highlights * Ended the second quarter with 112 direct sales representatives, an increase of three from last quarter, and up from 100 at the end of Q2 2019. * Active accounts in the second quarter were 789, an increase of 4% compared to 762 in the second quarter a year ago. * Ended the quarter with 126 peer-reviewed clinical publications featuring Axogen’s nerve repair product portfolio.RECON Clinical Study Enrollment and Follow-Up RECON is a pivotal clinical study supporting the Company’s Biologics License Application (BLA) for Avance® Nerve Graft. The study protocol requires a one-year follow-up assessment with an allowance for an additional three-month visit window. With the final subject enrolled in July of 2020, the last patient is expected to complete the study no later than October of 2021. The Company anticipates it will provide a preliminary report of study data in the second quarter of 2022 and expects to file the BLA in 2023.2020 Financial Guidance On April 1, 2020, the Company disclosed that it was suspending its 2020 annual financial guidance as previously provided on February 24, 2020 due to factors associated with COVID-19. At this date, the Company cannot predict the extent or duration of the impact of the COVID-19 pandemic on its financial results but expects the current environment will lead to revenues below the prior year in the third and fourth quarter. Conference Call The Company will host a conference call and webcast for the investment community today at 4:30 p.m. ET. Investors interested in participating by phone are invited to call toll free at 1-877-407-0993 or use the direct dial-in number 1-201-689-8795. Those interested in listening to the conference call live via the Internet can do so by visiting the Investors page of the Company’s website at www.axogeninc.com and clicking on the webcast link on the Investors home page.Following the conference call, a replay will be available on the Company’s website at www.axogeninc.com under Investors.About Axogen Axogen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or transection to peripheral nerves by providing innovative, clinically proven and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve, or the inability to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.Axogen's platform for peripheral nerve repair features a comprehensive portfolio of products, including Avance® Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; Axoguard® Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; Axoguard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments; Axoguard® Nerve Cap, a porcine submucosa ECM product used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive® Soft Tissue Membrane, a processed human umbilical cord intended for surgical use as a resorbable soft tissue barrier. The Axogen portfolio of products is available in the United States, Canada, the United Kingdom, South Korea, and several other European and international countries.Cautionary Statements Concerning Forward-Looking Statements This press release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events, or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “projects,” “forecasts,” “continue,” “may,” “should,” “will,” “goals,” and variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements related to the expected impact of COVID-19 on our business, statements regarding our growth, product development, product potential, financial performance, sales growth, product adoption, market awareness of our products, data validation, our assessment of our internal controls over financial reporting, our visibility at and sponsorship of conferences and educational events. The forward-looking statements are and will be subject to risks and uncertainties, which may cause actual results to differ materially from those expressed or implied in such forward-looking statements. Forward-looking statements contained in this press release should be evaluated together with the many uncertainties that affect our business and our market, particularly those discussed under Part I, Item 1A., “Risk Factors,” of our Annual Report on Form 10-K, as amended on Form 10-K/A, for the fiscal year ended December 31, 2019, as well as other risks and cautionary statements set forth in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements are not a guarantee of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made and, except as required by applicable law, we assume no responsibility to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances, or otherwise.About Non-GAAP Financial Measures To supplement our consolidated financial statements, we use the non-GAAP financial measures of EBITDA, which measures earnings before interest, income taxes, depreciation and amortization, and Adjusted EBITDA which further excludes non-cash stock compensation expense. We also use the non-GAAP financial measures of Adjusted Net Loss and Adjusted Net Loss Per Common Share - basic and diluted which excludes non-cash stock compensation expense and loss on extinguishment of debt from Net Loss and Net Loss Per Common Share - basic and diluted, respectively.
- 08/05/2020
|
The Daily Biotech Pulse: Novavax Vaccine Data, Aerpio Gets $5.1M Funding For COVID Trial, Rigel Gains Big On Earnings
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 4)
ABIOMED, Inc. (NASDAQ: ABMD) (FDA approved the emergency use of Abiomed's Impella heart pump in combination...
- 08/05/2020
|
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
- Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts.
COVID-19 news flow continued to pour in,...
- 08/02/2020
|
Earnings Preview: AxoGen (AXGN) Q2 Earnings Expected to Decline
- AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/29/2020
|
Axogen, Inc. to Present at the Canaccord Genuity 40th Annual Growth Conference
- ALACHUA, Fla., July 29, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president, will present at the Canaccord Genuity 40th Annual Growth Conference. The virtual presentation is scheduled for Wednesday, August 12, 2020 at 9:00 a.m. ET. The presentation will be webcast live and can be accessed through the Investors page at www.axogeninc.com. For those not available to listen to the live broadcast, a replay will be archived for 90 days and available through the Investors page on www.axogeninc.com.About Axogen Axogen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or transection to peripheral nerves by providing innovative, clinically proven and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve, or the inability to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.Axogen's platform for peripheral nerve repair features a comprehensive portfolio of products, including Avance® Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; Axoguard® Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; Axoguard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments; Axoguard® Nerve Cap, a porcine submucosa ECM product used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive® Soft Tissue Membrane, a processed human umbilical cord intended for surgical use as a resorbable soft tissue barrier. The Axogen portfolio of products is available in the United States, Canada, the United Kingdom, South Korea, and several other European and international countries.Contact: Axogen, Inc. Peter Mariani, Chief Financial Officer InvestorRelations@axogeninc.com
- 07/29/2020
|
BioNTech COVID-19 Progress, And Other News: The Good, Bad And Ugly Of Biopharma
- BioNTech reports positive COVID-19 vaccine data with Pfizer, receives $2 billion order from US Govt. AxoGen completes enrollment in pivotal nerve graft study.
- 07/23/2020
|
Axogen RECON Clinical Study Completes Target Enrollment of 220 Subjects
- RECON is a pivotal study supporting the Company’s Biologics License Application (BLA) for Avance® Nerve GraftALACHUA, Fla., July 22, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that its phase 3 pivotal RECONSM Clinical Study supporting its Biologics License Application (BLA) submission for Avance Nerve Graft has reached its enrollment target of 220 subjects. RECON compares Avance Nerve Graft to manufactured conduits in digital nerve injuries with a primary endpoint of return of sensation and secondary endpoints for quality of life and patient satisfaction. “We are pleased to have reached this important milestone and appreciate the dedication and commitment of each of the participating study teams,” commented Karen Zaderej, chairman, CEO, and president of Axogen. “Completing enrollment for the RECON Study is a critical step in transitioning our Avance Nerve Graft from classification as a section 361 HCT/P tissue product to a section 351 biological product.” The RECON Clinical Study protocol requires a one-year follow-up assessment with an additional three month visit window. With the final subject enrolled in July of 2020, the last patient is expected to complete the study no later than October of 2021. The company anticipates it will provide a preliminary report of trial data in the second quarter of 2022 and expects to file the BLA in 2023. About the RECON Clinical Study Comparison of Processed Nerve Allograft and Collagen Nerve Cuffs for Peripheral Nerve Repair (RECON) is a multicenter, prospective, randomized, subject, and evaluator blinded comparative clinical study of nerve cuffs and Avance Nerve Graft evaluating recovery outcomes for the repair of nerve discontinuities. The study is designed to test for non-inferiority between the static two-point discrimination outcomes for Avance Nerve Graft and nerve cuffs.About Avance Nerve Graft Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site. Avance provides structural guidance for regenerating axons, and revascularizes and remodels into the patient’s own tissue. It is available in a variety of lengths and diameters.In September 2018 the FDA granted a Regenerative Medicine Advance Therapy (RMAT) designation for Avance Nerve Graft. A regenerative medicine therapy is eligible for the designation if it is intended to treat, modify, reverse or cure a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the product has the potential to address unmet medical needs for such a disease or condition. The RMAT designation provides access to a streamlined approval process for regenerative medicine technologies and ensures continued informal meetings with the FDA in support of the BLA for Avance Nerve Graft.About Axogen Axogen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or transection to peripheral nerves by providing innovative, clinically proven and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve, or the inability to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.Axogen’s platform for peripheral nerve repair features a comprehensive portfolio of products, including Avance® Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; Axoguard® Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; Axoguard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments; Axoguard® Nerve Cap, a porcine submucosa ECM product used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive® Soft Tissue Membrane, a processed human umbilical cord intended for surgical use as a resorbable soft tissue barrier. The Axogen portfolio of products is available in the United States, Canada, the United Kingdom, South Korea, and several other European and international countries.Cautionary Statements Concerning Forward-Looking Statements This press release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations or predictions of future conditions, events, or results based on various assumptions and management’s estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “projects,” “forecasts,” “continue,” “may,” “should,” “will,” “goals,” and variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements related to the expected impact of COVID-19 on our business, statements regarding our growth, product development, product potential, financial performance, sales growth, product adoption, market awareness of our products, data validation, our assessment of our internal controls over financial reporting, our visibility at and sponsorship of conferences and educational events. The forward-looking statements are and will be subject to risks and uncertainties, which may cause actual results to differ materially from those expressed or implied in such forward-looking statements. Forward-looking statements contained in this press release should be evaluated together with the many uncertainties that affect our business and our market, particularly those discussed under Part I, Item 1A., “Risk Factors,” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as well as other risks and cautionary statements set forth in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements are not a guarantee of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made and, except as required by applicable law, we assume no responsibility to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances, or otherwise.Contact: Axogen, Inc. Peter Mariani, Chief Financial Officer InvestorRelations@axogeninc.com
- 07/22/2020
|
Axogen, Inc. to Report Second Quarter 2020 Financial Results and Host Conference Call on August 5, 2020
- ALACHUA, Fla., July 15, 2020 -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral.
- 07/15/2020
|
Is AxoGen, Inc. (AXGN) Going to Burn These Hedge Funds?
- Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]
- 07/08/2020
|
Squarepoint Ops LLC Makes New $200,000 Investment in AxoGen, Inc (NASDAQ:AXGN)
- Squarepoint Ops LLC bought a new position in shares of AxoGen, Inc (NASDAQ:AXGN) during the 1st quarter, according to its most recent filing with the SEC. The institutional investor bought 19,232 shares of the medical equipment provider’s stock, valued at approximately $200,000. A number of other institutional investors have also modified their holdings of AXGN. […]
- 07/08/2020
|
AxoGen (NASDAQ:AXGN) Trading 26.9% Higher
- AxoGen, Inc (NASDAQ:AXGN)’s stock price traded up 26.9% on Wednesday . The company traded as high as $12.72 and last traded at $11.73, 4,252,326 shares traded hands during trading. An increase of 744% from the average session volume of 503,598 shares. The stock had previously closed at $9.24. A number of equities analysts have weighed […]
- 07/03/2020
|
Canaccord Genuity Downgrades AxoGen (AXGN) to Hold - Markets
- Canaccord Genuity analyst Kyle Rose downgraded AxoGen (AXGN – Research Report) to Hold yesterday and set a price target of
- 07/02/2020
|
Analyst Explains Why They Downgraded Their Rating on AxoGen (AXGN) - Markets
- AxoGen (AXGN – Research Report) received a Hold rating from BTIG analyst Ryan Zimmerman today. The company’s shares closed last
- 07/01/2020
|
AXOGEN, INC. : Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K) | MarketScreener
|
Axogen Announces New Seven-Year Financing Agreement with Oberland Capital and Provides Preliminary Second Quarter Revenue Estimate
- Axogen, Inc. (AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced a financing agreement with Oberland Capital and provided preliminary, estimated revenue for the second quarter ended June 30, 2020. “We are pleased to announce this new debt facility with Oberland Capital,” noted Peter J. Mariani, chief financial officer of Axogen. “I am very pleased with the Axogen team’s commitment to our customers and the support we have provided as surgical schedules reopened during the quarter,” commented Karen Zaderej, chairman, CEO, and president of Axogen.
- 07/01/2020
|
Head-To-Head Analysis: AxoGen (NASDAQ:AXGN) versus Natus Medical (NASDAQ:NTUS)
- AxoGen (NASDAQ:AXGN) and Natus Medical (NASDAQ:NTUS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability and institutional ownership. Institutional and Insider Ownership 82.5% of AxoGen shares are owned by institutional investors. Comparatively, 89.2% of […]
- 06/26/2020
|
AxoGen, Inc (NASDAQ:AXGN) Stock Holdings Increased by Rhumbline Advisers
- Rhumbline Advisers raised its position in shares of AxoGen, Inc (NASDAQ:AXGN) by 2.3% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 46,125 shares of the medical equipment provider’s stock after buying an additional 1,030 shares during the quarter. Rhumbline Advisers’ holdings in AxoGen […]
- 06/10/2020
|
Axogen, Inc. Announces Planned Retirement of Greg Freitag and Appoints Brad Ottinger as General Counsel and Chief Compliance Officer
- Axogen, Inc. (AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced the appointment of Brad Ottinger as General Counsel and Chief Compliance Officer. Ottinger has extensive experience in the medical device industry and holds professional certifications in corporate compliance and ethics.
- 06/01/2020
|
Edited Transcript of AXGN earnings conference call or presentation 6-May-20 8:30pm GMT
- Q1 2020 AxoGen Inc Earnings Call
- 06/01/2020
|
Axogen, Inc. Announces Planned Retirement of Greg Freitag and Appoints Brad Ottinger as General ...
|
96 Biggest Movers From Yesterday
|
Axogen, Inc. to Present at the Jefferies Virtual Healthcare Conference
- ALACHUA, Fla., May 20, 2020 -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral.
- 05/20/2020
|
Axogen, Inc. to Present at the Jefferies Virtual Healthcare Conference
|
AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q1 2020 Results - Earnings Call Transcript
- AxoGen, Inc. (NASDAQ:AXGN) Q1 2020 Earnings Conference Call May 06, 2020 16:30 A.M. ET Company Participants Karen Zaderej - Chairman, President, and CEO Peter J
- 05/08/2020
|
84 Biggest Movers From Yesterday
|
AxoGen Inc (AXGN) Q1 2020 Earnings Call Transcript
- Joining me on today's call is Karen Zaderej, AxoGen's Chairman, Chief Executive Officer and President. Karen will begin our call with an overview of our Q1 performance, our response to the COVID-19 pandemic and provide an outlook on the developing recovery. Today's call is being broadcast live via webcast, which is available on the Investors section of the AxoGen website.
- 05/07/2020
|
U.S. RESEARCH ROUNDUP-Ashland Global, Lyft, Solaredge Technologies
- Wall Street securities analysts on Thursday revised their ratings and
price targets on several U.S.-listed companies, including Ashland Global Holdings, Lyft and
Solaredge Technologies.
HIGHLIGHTS
* Ashland Global Holdings Inc. : JP Morgan raises to neutral from underweight
* Lyft Inc : Piper Sandler cuts to neutral from overweight
* Natera Inc : JP Morgan raises to overweight from neutral
* Occidental Petroleum Corp : SunTrust Robinson raises to hold from sell
* Solaredge Technologies : Canaccord Genuity cuts to hold from buy
Following is a summary of research actions on U.S. companies reported by Reuters on Thursday.
Stock entries are in alphabetical order.
* A. O. Smith Corp : Stephens raises target price to $40 from $37
* Acadia Healthcare Company Inc : Citigroup cuts price target to $34 from $37
* Acadia Healthcare Company Inc : Deutsche Bank cuts target price to $28 from $32
* Activision Blizzard Inc : Keybanc raises target price to $80 from $68
* Adient Plc : Deutsche Bank raises target price to $20 from $15
* ADMA Biologics Inc : Oppenheimer cuts target price to $7 from $14
* Advanced Energy Industries Inc : Citigroup raises price target to $63 from $40
* Advanced Energy Industries Inc : Cowen and Company raises PT to $58 from $51
* Advanced Energy Industries Inc : D.A. Davidson raises target to $60 from $50
* Advanced Energy Industries Inc : Susquehanna cuts target price to $85 from $90
* Aerie Pharmaceuticals Inc : H.C. Wainwright cuts target price to $31 from $37
* Aerie Pharmaceuticals Inc : Mizuho cuts target price to $29 from $34
* Aerie Pharmaceuticals Inc : Piper Sandler cuts target price to $35 from $45
* Aerie Pharmaceuticals Inc : SunTrust Robinson cuts price target to $22 from $26
* Agco Corp : Stephens raises target price to $65 from $60
* Air Transport Services Group Inc : Cowen and Company raises PT to $26 from $25
* Albemarle Corp : UBS cuts target price to $90 from $98
* Alexion Pharmaceuticals Inc : BMO cuts target price to $142 from $147
* Alexion Pharmaceuticals Inc : Credit Suisse cuts target price to $142 from $147
* Alexion Pharmaceuticals Inc : Jefferies cuts price target to $111 from $112
* Alexion Pharmaceuticals Inc : Raymond James cuts target price to $156 from $159
* Alexion Pharmaceuticals Inc : SunTrust Robinson cuts target to $135 from $141
* Alexion Pharmaceuticals Inc : SVB Leerink cuts target price to $150 from $156
* Allegiant Travel Co : Cowen and Company cuts price target to $74 from $100
* Allete Inc : Guggenheim cuts price target to $65 from $70
* Allogene Therapeutics Inc : Jefferies raises target price to $37 from $36
* Allstate Corp : Piper Sandler raises target price to $112 from $108
* Alnylam Pharmaceuticals Inc : Guggenheim raises price target to $166 from $155
* Alnylam Pharmaceuticals Inc : BMO raises target price to $171 from $145
* Alnylam Pharmaceuticals Inc : Jefferies raises price target to $165 from $142
* Alnylam Pharmaceuticals Inc : JP Morgan cuts to neutral from overweight
* Alnylam Pharmaceuticals Inc : JP Morgan raises target price to $137 from $133
* Alnylam Pharmaceuticals Inc : Needham raises target price to $160 from $135
* Alnylam Pharmaceuticals Inc : Oppenheimer raises target price to $162 from $140
* Alnylam Pharmaceuticals Inc : Piper Sandler raises target to $169 from $142
* Alteryx Inc : Citigroup cuts price target to $147 from $160
* Alteryx Inc : Cowen and Company cuts target price to $135 from $145
* Alteryx Inc : Needham cuts target price to $140 from $152
* Alteryx Inc : Wedbush cuts price target to $138 from $146
* Amedisys Inc : Benchmark cuts to hold rating
* Ameriprise Financial Inc : Evercore ISI raises target price to $139 from $136
* Ametek Inc : Berenberg raises target price to $93 from $86
* Ametek Inc : Stephens cuts target price to $92 from $94
* Anaptysbio Inc : Credit Suisse raises target price to $16 from $14
* Apache Corp : Credit Suisse raises target price to $10 from $4
* Aptiv Plc : Deutsche Bank raises target price to $75 from $59
* Arcus Biosciences Inc : Wedbush raises target price to $40 from $26
* Ares Capital Corp : BMO cuts target price by $5 to $16
* Ares Capital Corp : Citigroup raises price target to $15 from $13
* Ares Management Corp : BMO raises target price to $40 from $30
* Ares Management Corp : Credit Suisse raises target price to $40 from $38
* Ares Management Corp : Jefferies raises target price to $42 from $39
* Ares Management Corp : KBW raises target price to $45 from $44
* ASGN Inc : Jefferies raises target price to $54 from $31
* Ashland Global Holdings Inc : Deutsche Bank raises target price to $70 from $65
* Ashland Global Holdings Inc. : JP Morgan cuts target price to $62 from $68
* Ashland Global Holdings Inc. : JP Morgan raises to neutral from underweight
* Ashland Global Holdings Inc. : SunTrust Robinson cuts price target to $75 from $87
* Aspen Technology Inc : Benchmark cuts target price to $130
* Aspen Technology Inc : Keybanc raises target price to $120 from $110
* Assetmark Financial Holdings Inc : BMO cuts target price to $23 from $26
* Assurant Inc : SunTrust Robinson cuts price target to $145 from $155
* Astronics Corp : Canaccord Genuity cuts target price to $10 from $14
* Astronics Corp : SunTrust Robinson cuts price target to $6 from $7
* Atkore International Group Inc : Citigroup raises price target to $26 from $24
* Atlas Corp (British Columbia) : Citigroup cuts price target to $7 from $12
* Avanos Medical Inc : Berenberg raises target price to $33 from $30
* Avanos Medical Inc : Stephens raises target price to $38 from $30
* Axalta Coating Systems Ltd : Citigroup raises price target to $21 from $18
* Axalta Coating Systems Ltd : Credit Suisse cuts target price to $27 from $29
* Axalta Coating Systems Ltd : Jefferies raises target price to $18 from $15
* Axalta Coating Systems Ltd : Keybanc raises target price to $24 from $23
* Axcelis Technologies Inc : D.A. Davidson raises price target to $25 from $20
* Axcella Health Inc : BTIG raises target price to $12 from $10
* Axogen Inc : Canaccord Genuity cuts target price to $12 from $22
* Axogen Inc : Jefferies cuts target price to $21 from $30
* Bank of N.T. Butterfield & Son Ltd : Citigroup raises target to $21 from $15
* Barrett Business Services Inc : Barrington Research raises PT to $52 from $48
* Barrick Gold Corp : Deutsche Bank raises target price to $34 from $25
* Benefitfocus Inc : Piper Sandler cuts target price to $26 from $35
* Bio Rad Laboratories Inc : Citigroup raises price target to $525 from $480
* Bio Rad Laboratories Inc : Jefferies raises target price to $525 from $500
* Biocryst Pharmaceuticals Inc : Jefferies raises price target to $9 from $8
* Biocryst Pharmaceuticals Inc : Piper Sandler raises target price to $10 from $8
* Biotelemetry Inc : Benchmark cuts target price to $52 from $55
* Black Knight Inc : KBW raises target price to $70 from $68
* Black Knight Inc : Stephens raises target price to $88 from $84
* Black Knight Inc : Wedbush raises target price to $70 from $66
* Black Stone Minerals LP : Simmons Energy raises target price to $8 from $5
* Blackbaud Inc : Evercore ISI cuts target price to $48 from $55
* Blucora Inc : Benchmark cuts price target to $25 from $37
* BMC stock Holdings Inc : Stephens raises target price to $25 from $22
* BMC stock Holdings Inc : SunTrust Robinson raises price target to $26 from $22
* BorgWarner Inc : Jefferies raises target price to $33 from $30
* BorgWarner Inc : JP Morgan raises price target to $35 from $32
* BorgWarner Inc : Oppenheimer cuts target price to $44 from $45
* BorgWarner Inc : RBC raises target price to $31 from $29
* Boston Private Financial Holdings Inc : Piper Sandler raises PT to $7 from $6.
- 05/07/2020
|
Benzinga's Top Upgrades, Downgrades For May 7, 2020
|
Canaccord Genuity Downgrades Axogen to Hold, Announces $12 Price Target
|
Edited Transcript of AXGN earnings conference call or presentation 6-May-20 8:30pm GMT
- Q1 2020 AxoGen Inc Earnings Call
- 05/07/2020
|
U.S. RESEARCH ROUNDUP-Ashland Global Holdings, Lyft, Solaredge Technologies
- Wall Street securities analysts revised their ratings and price targets on
several U.S.-listed companies, including Ashland Global Holdings, Lyft and Solaredge
Technologies, on Thursday.
HIGHLIGHTS
* Ashland Global Holdings Inc. : JP Morgan raises to neutral from underweight
* Lyft Inc : Piper Sandler cuts to neutral from overweight
* Natera Inc : JP Morgan raises to overweight from neutral
* Occidental Petroleum Corp : SunTrust Robinson raises to hold from sell
* Solaredge Technologies : Canaccord Genuity cuts to hold from buy
Following is a summary of research actions on U.S. companies reported by Reuters on Thursday.
Stock entries are in alphabetical order.
* Acadia Healthcare Company Inc : Citigroup cuts price target to $34 from $37
* Activision Blizzard Inc : Keybanc raises target price to $80 from $68
* Advanced Energy Industries Inc : Susquehanna cuts target price to $85 from $90
* Agco Corp : Stephens raises target price to $65 from $60
* Alexion Pharmaceuticals Inc : Credit Suisse cuts target price to $142 from $147
* Allegiant Travel Co : Cowen and Company cuts price target to $74 from $100
* Allstate Corp : Piper Sandler raises target price to $112 from $108
* Alnylam Pharmaceuticals Inc : JP Morgan cuts to neutral from overweight
* Alnylam Pharmaceuticals Inc : JP Morgan raises target price to $137 from $133
* Alnylam Pharmaceuticals Inc : Needham raises target price to $160 from $135
* Alnylam Pharmaceuticals Inc : Piper Sandler raises target price to $169 from $142
* Anaptysbio Inc : Credit Suisse raises target price to $16 from $14
* Arcus Biosciences Inc : Wedbush raises target price to $40 from $26
* Ares Management Corp : Credit Suisse raises target price to $40 from $38
* Ashland Global Holdings Inc. : JP Morgan raises to neutral from underweight
* Ashland Global Holdings Inc. : JP Morgan cuts target price to $62 from $68
* Aspen Technology Inc : Keybanc raises target price to $120 from $110
* Astronics Corp : Canaccord Genuity cuts target price to $10 from $14
* Atkore International Group Inc : Citigroup raises price target to $26 from $24
* Atlas Corp (British Columbia) : Citigroup cuts price target to $7 from $12
* Axalta Coating Systems Ltd : Credit Suisse cuts target price to $27 from $29
* Axalta Coating Systems Ltd : Keybanc raises target price to $24 from $23
* Axogen Inc : Canaccord Genuity cuts target price to $12 from $22
* Bank of N.T. Butterfield & Son Ltd : Citigroup raises price target to $21 from $15
* Benefitfocus Inc : Piper Sandler cuts target price to $26 from $35
* Biocryst Pharmaceuticals Inc : Piper Sandler raises target price to $10 from $8
* Black Knight Inc : Stephens raises target price to $88 from $84
* Black Stone Minerals LP : Simmons Energy raises target price to $8 from $5
* Boston Private Financial Holdings Inc : Piper Sandler raises PT to $7 from $6.50
* Brookfield Business Partners LP : National Bank of Canada cuts PT to $38 from $42
* Brookfield Renewable Partners LP : CIBC raises target price to $49 from $48
* Catalent Inc : Stephens raises target price to $82 from $75
* Central Garden & Pet Co : Keybanc raises target price to $38 from $35
* Ceridian Hcm Holding Inc : Credit Suisse raises target price to $49 from $47
* Chefs' Warehouse Inc : Jefferies raises target price to $13 from $12
* Chemours Co : Jefferies raises target price to $13 from $11
* CNH Industrial : JP Morgan cuts target price to $6.50 from $8
* Consolidated Edison Inc : Credit Suisse cuts target price to $78 from $92
* Constellation Pharmaceuticals Inc : Jefferies raises target price to $63 from $53
* Lendingclub Corp : BTIG cuts target price to $11 from $23
* Cubic Corp : Canaccord Genuity cuts target price to $48 from $55
* Cytosorbents Corp : MKM Partners raises target price to $14 from $8
* Devon Energy Corp : Simmons Energy raises target price to $10 from $6
* Discovery Inc : MKM Partners cuts target price to $26 from $30
* Dupont : Citigroup raises price target to $52 from $47
* Dupont : Jefferies raises target price to $53 from $49
* Elevate Credit Inc : Credit Suisse cuts target price to $4 from $4.75
* Etsy Inc : Canaccord Genuity raises target price to $85 from $70
* Etsy Inc : Jefferies raises target price to $71 from $66
* Everbridge Inc : Stephens raises target price to $125 from $120
* Eversource Energy : Credit Suisse cuts target price to $81 from $92
* Evoqua Water Technologies Corp : Stifel raises target price to $22 from $21
* Exact Sciences Corp : Cowen and Company raises target price to $95 from $90
* Fastly Inc : Piper Sandler raises target price to $31 from $27
* First Western Financial Inc : Stephens cuts target price to $15 from $17
* Flir Systems Inc : Needham raises target price to $52 from $48
* FMC Corp : Citigroup raises price target to $114 from $107
* FMC Corp : Keybanc raises target price to $108 from $93
* Formfactor Inc : Cowen and Company raises target price to $24 from $22
* Formfactor Inc : D.A. Davidson raises target price to $25 from $20
* Fortinet Inc : Credit Suisse raises target price to $110 from $100
* Fortinet Inc : Piper Sandler raises target price to $125 from $110
* Fox Factory Holding Corp : Jefferies raises target price to $65 from $60
* Frontdoor Inc : Credit Suisse cuts target price to $44 from $50
* Gibraltar Industries Inc : Keybanc cuts target price to $55 from $60
* Global Payments Inc : Credit Suisse raises target price to $200 from $190
* Global Payments Inc : Jefferies raises target price to $195 from $175
* Global Payments Inc : Susquehanna raises target price to $205 from $200
* Graftech International Ltd : Credit Suisse cuts target price to $13 from $17
* Grubhub Inc : Jefferies raises target price to $50 from $48
* Heron Therapeutics Inc : Jefferies cuts target price to $31 from $33
* Hubspot Inc : Jefferies raises target price to $202 from $150
* Immunomedics Inc : Jefferies raises target price to $41 from $25
* Inmode Ltd : Canaccord Genuity cuts target price to $40 from $50
* Kennametal Inc : CFRA cuts target price to $25 from $32
* Kennametal Inc : JP Morgan cuts target price to $27 from $31
* Kforce Inc : Credit Suisse raises target price to $32 from $26
* KKR & Co Inc : Credit Suisse raises target price to $29 from $27
* Livongo Health Inc : Canaccord Genuity raises target price to $65 from $46
* Livongo Health Inc : Keybanc raises target price to $52 from $46
* Lyft Inc : D.A. Davidson raises target price to $35 from $27
* Lyft Inc : Jefferies cuts target price to $50 from $60
* Lyft Inc : Piper Sandler cuts price target to $31 from $63
* Lyft Inc : Piper Sandler cuts to neutral from overweight
* Magellan Midstream Partners LP : Credit Suisse raises target price to $48 from $42
* Martin Marietta Materials Inc : Citigroup raises price target to $230 from $228
* Natera Inc : Canaccord Genuity raises target price to $48 from $46
* Natera Inc : JP Morgan raises to overweight from neutral
* Natera Inc : JP Morgan raises target price to $45 from $32
* National Energy Services Reunited : National Bank of Canada cuts PT to $12 from
$13
* Neurocrine Biosciences Inc : Canaccord Genuity raises target to $123 from $122
* Neurocrine Biosciences Inc : Jefferies raises target price to $119 from $115
* Neurocrine Biosciences Inc : Mizuho raises target price to $105 from $103
* Neurocrine Biosciences Inc : Piper Sandler raises target price to $126 from $125
* Nlight Inc : Canaccord Genuity cuts target price to $22 from $25
* Now Inc : Stifel cuts target price to $6 from $7
* Nuvasive Inc : Canaccord Genuity cuts target price to $64 from $68
* Nuvasive Inc : Piper Sandler cuts target price to $75 from $90
* Occidental Petroleum Corp : SunTrust Robinson raises to hold from sell
* Occidental Petroleum Corp : SunTrust Robinson raises price target to $13 from $10
* Occidental Petroleum Corp : Susquehanna cuts target price to $12 from $13
* Palomar Holdings Inc : Piper Sandler raises target price to $64 from $54
* Papa John's International Inc : Credit Suisse raises target price to $84 from $71
* Papa John's International Inc : MKM Partners raises target price to $72 from $70
* Papa John's International Inc : Stifel raises target price to $95 from $80
* Parsley Energy Inc : Simmons Energy raises target price to $8 from $7.
- 05/07/2020
|
68 Stocks Moving In Thursday's Mid-Day Session
|
Axogen Withdraws Its FY20 Guidance Due To Coronavirus
|
Axogen Q1 EPS $(0.190) Misses $(0.150) Estimate, Sales $24.300M Miss $26.190M Estimate
|
Axogen, Inc. Reports First Quarter 2020 Financial Results
- ALACHUA, Fla., May 06, 2020 -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today.
- 05/06/2020
|
The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peak
(Biotech Stocks Hitting 52-week Highs May 5)
• Adverum Biotechnologies...
- 05/06/2020
|
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
- Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
- 05/03/2020
|
AxoGen (NASDAQ:AXGN) Upgraded by BidaskClub to Hold
- AxoGen (NASDAQ:AXGN) was upgraded by BidaskClub from a “sell” rating to a “hold” rating in a research report issued on Thursday, BidAskClub reports. AXGN has been the topic of a number of other research reports. ValuEngine lowered shares of AxoGen from a “strong-buy” rating to a “buy” rating in a research note on Thursday, April […]
- 04/30/2020
|
The VP, Clinical&Translational Sc of AxoGen (AXGN) is Buying Shares
- Yesterday, the VP, Clinical&Translational Sc of AxoGen (AXGN), Erick Wayne Devinney, bought shares of AXGN for $683. This recent transaction increases
- 04/30/2020
|
The VP, Clinical&Translational Sc of AxoGen (NASDAQ: AXGN) is Buying Shares
- Yesterday, the VP, Clinical&Translational Sc of AxoGen (
AXGN
–
Research Report
),
Erick Wayne Devinney
, bought shares of AXGN for $683.
This recent transaction increases Erick Wayne Devinney’s holding in the company by 5.21% to a total of $463.6K.
- 04/30/2020
|
Earnings Preview: AxoGen (AXGN) Q1 Earnings Expected to Decline
- AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/29/2020
|
Earnings Preview: AxoGen (AXGN) Q1 Earnings Expected to Decline
- AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/29/2020
|
AxoGen (AXGN) Scheduled to Post Earnings on Wednesday
- AxoGen (NASDAQ:AXGN) will issue its quarterly earnings data after the market closes on Wednesday, May 6th. Analysts expect the company to announce earnings of ($0.20) per share for the quarter. AxoGen has set its FY 2020 After-Hours guidance at EPS.Individual that wish to register for the company’s earnings conference call can do so using this […]
- 04/29/2020
|
AxoGen, Inc (NASDAQ:AXGN) Shares Sold by Nuveen Asset Management LLC
- Nuveen Asset Management LLC decreased its holdings in shares of AxoGen, Inc (NASDAQ:AXGN) by 3.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 155,029 shares of the medical equipment provider’s stock after selling 4,986 shares during the period. Nuveen Asset Management LLC owned […]
- 04/27/2020
|
Reviewing AxoGen (NASDAQ:AXGN) & InMode (NASDAQ:INMD)
- AxoGen (NASDAQ:AXGN) and InMode (NASDAQ:INMD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, profitability, valuation and earnings. Insider and Institutional Ownership 83.9% of AxoGen shares are held by institutional investors. Comparatively, 11.2% of InMode […]
- 04/25/2020
|
Axogen Option Alert: Jun 19 $10 Calls Sweep (3) near the Ask: 1000 @ $0.604 vs 1 OI; Earnings 5/6 After Close Ref=$8.345
|
Analysts' Top Healthcare Picks: Edwards Lifesciences (EW), AxoGen (AXGN)
- There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Edwards Lifesciences (EW) and AxoGen (AXGN) with bullish
- 04/24/2020
|
Analysts’ Top Healthcare Picks: Edwards Lifesciences (EW), AxoGen (AXGN)
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Edwards Lifesciences (
EW
–
Research Report
) and AxoGen (
AXGN
–
Research Report
) with bullish sentiments.
Edwards Lifesciences (EW)
Canaccord Genuity an
- 04/24/2020
|
Analysts Offer Insights on Healthcare Companies: AxoGen (AXGN) and Sanofi (OtherSNYNF)
- Analysts have been eager to weigh in on the Healthcare sector with new ratings on AxoGen (AXGN) and Sanofi (SNYNF). AxoGen (AXGN) In a report released
- 04/23/2020
|
Analysts Offer Insights on Healthcare Companies: AxoGen (NASDAQ: AXGN) and Sanofi (Other OTC: SNYNF)
- Analysts have been eager to weigh in on the Healthcare sector with new ratings on AxoGen (AXGN – Research Report)
- 04/23/2020
|
Axogen sees Q1 revenue of ~$24M; class action lawsuit dismissed
- Axogen (NASDAQ:AXGN) announces preliminary Q1 revenue and a business update in response to the COVID-19 pandemic. Q1 2020 net revenue is estimated to be ~$24.3M (+4% Y/Y). The Company plans to reduce
- 04/23/2020
|
AxoGen expects pandemic to negatively impact Q2 revenue AXGN
- AxoGen expects pandemic to negatively impact Q2 revenue AXGN
- 04/23/2020
|
AxoGen lays off approx. 10% of workforce, implements hiring freeze AXGN
- AxoGen lays off approx. 10% of workforce, implements hiring freeze AXGN
- 04/23/2020
|
AxoGen sees Q1 revenue $24.3M, consensus $27.06M AXGN
- AxoGen sees Q1 revenue $24.3M, consensus $27.06M AXGN
- 04/23/2020
|
AxoGen announces $7.8M loan under PPP AXGN
- AxoGen announces $7.8M loan under PPP AXGN
- 04/23/2020
|
Axogen, Inc. Reports Preliminary Revenue for the First Quarter 2020, Provides Business Update in Response to COVID-19 Pandemic, and Announces Dismissal of Class Action Lawsuit
- Axogen, Inc. (AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced preliminary first quarter 2020 revenue, provided a business update on its actions in response to the COVID-19 pandemic, and announced the dismissal of its class-action lawsuit. Although revenue exiting February was trending toward the Company’s annual guidance, hospital reallocation of resources toward the COVID-19 pandemic, along with deferrals and restrictions placed on elective procedures, had a material negative impact on revenue in March. Additionally, management believes that demand for the Company’s products has been temporarily reduced as nationwide shelter-in-place orders have lowered the incidence of traumatic injuries.
- 04/23/2020
|
Axogen Sees Prelim. Q1 Sales $24.3M vs $27.06M Est.
|
The CEO of AxoGen (AXGN) is Buying Shares
- Today, the CEO of AxoGen (AXGN), Karen Zaderej, bought shares of AXGN for $55.92K. This recent transaction increases Karen Zaderej's holding in the
- 04/20/2020
|
The CEO of AxoGen (NASDAQ: AXGN) is Buying Shares
- Today, the CEO of AxoGen (
AXGN
–
Research Report
),
Karen Zaderej
, bought shares of AXGN for $55.92K.
This recent transaction increases Karen Zaderej’s holding in the company by 1.8% to a total of $5.08 million.
See today’s analyst top recommended
- 04/20/2020
|
AxoGen, Inc (NASDAQ:AXGN) Shares Sold by Goldman Sachs Group Inc.
- Goldman Sachs Group Inc. lowered its stake in shares of AxoGen, Inc (NASDAQ:AXGN) by 55.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 57,133 shares of the medical equipment provider’s stock after selling 72,125 shares during the quarter. […]
- 04/19/2020
|
Companies Like AxoGen (NASDAQ:AXGN) Are In A Position To Invest In Growth
- We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
- 04/18/2020
|
The Daily Biotech Pulse: Moderna Secures $483M In BARDA Funding, Gilead Remdesivir Data, Veracyte's Positive Pre-Announcement
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs April 16.)
Abbott Laboratories (...
- 04/17/2020
|
Stocks That Hit 52-Week Lows On Thursday
- During Thursday's morning session, 33 stocks hit new 52-week lows.
Significant Points:
America Movil (NYSE: AMX) was the largest, in terms of market cap, to set a...
- 04/16/2020
|
The Daily Biotech Pulse: FDA Nod For UroGen, Novavax Coronavirus Vaccine To Enter Clinics, Soligenix Licenses Vaccine Adjuvant
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs April 15.)
Bio-Rad Laboratories,...
- 04/16/2020
|
Exchange Traded Concepts LLC Acquires 7,738 Shares of AxoGen, Inc (NASDAQ:AXGN)
- Exchange Traded Concepts LLC grew its holdings in shares of AxoGen, Inc (NASDAQ:AXGN) by 135.5% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,450 shares of the medical equipment provider’s stock after acquiring an additional 7,738 shares during the […]
- 04/16/2020
|
Axogen, Inc. to Report First Quarter 2020 Financial Results and Host Conference Call on May 6, 2020
- Axogen, Inc. (AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report first quarter 2020 financial results on Wednesday, May 6, 2020 after the market closes. Axogen management will host an investment-community conference call and webcast following the release at 4:30 p.m. ET. Axogen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair.
- 04/15/2020
|
Axogen, Inc. to Report First Quarter 2020 Financial Results and Host Conference Call on May 6, 2020
- ALACHUA, Fla., April 15, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions...
- 04/15/2020
|
Stocks That Hit 52-Week Lows On Wednesday
|
AxoGen, Inc (NASDAQ:AXGN) Shares Sold by UBS Asset Management Americas Inc.
- UBS Asset Management Americas Inc. reduced its position in AxoGen, Inc (NASDAQ:AXGN) by 11.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 35,020 shares of the medical equipment provider’s stock after selling 4,540 shares during the quarter. UBS Asset Management Americas Inc. owned about […]
- 04/13/2020
|
Is AxoGen, Inc.'s (NASDAQ:AXGN) CEO Being Overpaid?
- Karen Zaderej has been the CEO of AxoGen, Inc. (NASDAQ:AXGN) since 2011. This analysis aims first to contrast CEO...
- 04/12/2020
|
Macquarie Group Ltd. Sells 3,665 Shares of AxoGen, Inc (NASDAQ:AXGN)
- Macquarie Group Ltd. cut its holdings in AxoGen, Inc (NASDAQ:AXGN) by 5.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 59,453 shares of the medical equipment provider’s stock after selling 3,665 shares during the period. Macquarie Group Ltd. owned 0.15% of AxoGen […]
- 04/12/2020
|
BidaskClub Downgrades AxoGen (NASDAQ:AXGN) to Sell
- AxoGen (NASDAQ:AXGN) was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Thursday, BidAskClub reports. Several other equities analysts also recently commented on AXGN. BTIG Research downgraded shares of AxoGen from a “buy” rating to a “neutral” rating in a report on Thursday, […]
- 04/11/2020
|
Contrasting Stereotaxis (OTCMKTS:STXS) & AxoGen (OTCMKTS:AXGN)
- AxoGen (NASDAQ:AXGN) and Stereotaxis (OTCMKTS:STXS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, institutional ownership and valuation. Insider & Institutional Ownership 83.9% of AxoGen shares are held by institutional investors. Comparatively, 20.8% of Stereotaxis […]
- 04/11/2020
|
Credit Suisse AG Reduces Stake in AxoGen, Inc (NASDAQ:AXGN)
- Credit Suisse AG lowered its stake in shares of AxoGen, Inc (NASDAQ:AXGN) by 8.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 23,747 shares of the medical equipment provider’s stock after selling 2,175 shares during the period. Credit Suisse AG […]
- 04/08/2020
|
Bank of New York Mellon Corp Sells 121,520 Shares of AxoGen, Inc (NASDAQ:AXGN)
- Bank of New York Mellon Corp reduced its stake in AxoGen, Inc (NASDAQ:AXGN) by 12.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 875,825 shares of the medical equipment provider’s stock after selling 121,520 shares during the […]
- 04/08/2020
|
AxoGen (NASDAQ:AXGN) versus SpectraScience (NASDAQ:SCIE) Financial Review
- AxoGen (NASDAQ:AXGN) and SpectraScience (OTCMKTS:SCIE) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability. Volatility & Risk AxoGen has a beta of 0.63, suggesting that its stock price is 37% less volatile […]
- 04/08/2020
|
-$0.14 EPS Expected for AxoGen, Inc (NASDAQ:AXGN) This Quarter
- Equities research analysts expect that AxoGen, Inc (NASDAQ:AXGN) will announce earnings of ($0.14) per share for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for AxoGen’s earnings, with estimates ranging from ($0.21) to ($0.07). AxoGen reported earnings per share of ($0.15) in the same quarter last year, which would indicate a […]
- 04/06/2020
|
Advisors Asset Management Inc. Decreases Position in AxoGen, Inc (NASDAQ:AXGN)
- Advisors Asset Management Inc. reduced its position in shares of AxoGen, Inc (NASDAQ:AXGN) by 25.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 21,425 shares of the medical equipment provider’s stock after selling 7,485 shares during the period. Advisors Asset […]
- 04/05/2020
|
AxoGen, Inc (NASDAQ:AXGN) Expected to Announce Quarterly Sales of $27.05 Million
- Wall Street brokerages predict that AxoGen, Inc (NASDAQ:AXGN) will report sales of $27.05 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for AxoGen’s earnings, with the lowest sales estimate coming in at $26.90 million and the highest estimate coming in at $27.20 million. AxoGen reported sales of […]
- 04/05/2020
|
AxoGen, Inc (NASDAQ:AXGN) Shares Purchased by Bank of America Corp DE
- Bank of America Corp DE increased its position in shares of AxoGen, Inc (NASDAQ:AXGN) by 13.7% during the 4th quarter, Holdings Channel.com reports. The fund owned 873,582 shares of the medical equipment provider’s stock after acquiring an additional 104,964 shares during the period. Bank of America Corp DE’s holdings in AxoGen were worth $15,628,000 at […]
- 04/03/2020
|
AxoGen, Inc (NASDAQ:AXGN) Short Interest Up 7.0% in March
- AxoGen, Inc (NASDAQ:AXGN) was the target of a large growth in short interest in the month of March. As of March 13th, there was short interest totalling 1,625,900 shares, a growth of 7.0% from the February 27th total of 1,520,000 shares. Currently, 4.5% of the company’s shares are short sold. Based on an average trading […]
- 04/03/2020
|
's Top Upgrades, Downgrades For April 2, 2020
- Upgrades
Credit Suisse changed the rating for MPLX LP (NYSE: MPLX) from Neutral to Outperform. For the fourth quarter, MPLX had an EPS of $0.58, compared to year-...
- 04/02/2020
|
Morgan Stanley likes Bristol-Myers Squibb in premarket analyst action
- Exact Sciences (NASDAQ:EXAS) initiated with an Outperform rating and a $70 (25% upside) price target at Evercore ISI.Health Catalyst (NASDAQ:HCAT) initiated with a Buy rating and a $40 (47% upside) pr
- 04/02/2020
|
AxoGen downgraded to Neutral from Buy at BTIG AXGN
- AxoGen downgraded to Neutral from Buy at BTIG BTIG AXGN
- 04/02/2020
|
AxoGen downgraded to Neutral from Buy at BTIG AXGN
- AxoGen downgraded to Neutral from Buy at BTIG BTIG AXGN
- 04/02/2020
|
Analysts Offer Insights on Healthcare Companies: Nevro Crop (NVRO), Inspire Medical Systems (INSP) and AxoGen (AXGN)
- Analysts have been eager to weigh in on the Healthcare sector with new ratings on Nevro Crop (NVRO), Inspire Medical Systems (INSP) and AxoGen (AXGN).
- 04/02/2020
|
Analysts Offer Insights on Healthcare Companies: Nevro Crop (NYSE: NVRO), Inspire Medical Systems (NYSE: INSP) and AxoGen (NASDAQ: AXGN)
- Analysts have been eager to weigh in on the Healthcare sector with new ratings on Nevro Crop (NVRO – Research
- 04/02/2020
|
BTIG Downgrades Axogen to Neutral
|
AxoGen suspends previous guidance, RECON study enrollment may get delayed AXGN
- AxoGen suspends previous guidance, RECON study enrollment may get delayed AXGN
- 04/01/2020
|
AlphaCrest Capital Management LLC Purchases Shares of 11,929 AxoGen, Inc (NASDAQ:AXGN)
- AlphaCrest Capital Management LLC purchased a new stake in AxoGen, Inc (NASDAQ:AXGN) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 11,929 shares of the medical equipment provider’s stock, valued at approximately $213,000. A number of other hedge funds also recently bought and sold […]
- 03/24/2020
|
Have Insiders Been Buying AxoGen, Inc. (NASDAQ:AXGN) Shares?
- We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
- 03/23/2020
|
ArrowMark Colorado Holdings LLC Has $106.96 Million Stake in AxoGen, Inc (NASDAQ:AXGN)
- ArrowMark Colorado Holdings LLC grew its holdings in shares of AxoGen, Inc (NASDAQ:AXGN) by 11.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,978,578 shares of the medical equipment provider’s stock after acquiring an additional 594,752 shares during the quarter. […]
- 03/18/2020
|
Charles Schwab Investment Management Inc. Grows Stake in AxoGen, Inc (NASDAQ:AXGN)
- Charles Schwab Investment Management Inc. increased its holdings in shares of AxoGen, Inc (NASDAQ:AXGN) by 2.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 214,683 shares of the medical equipment provider’s stock after purchasing an additional 4,576 shares during the quarter. […]
- 03/15/2020
|
AxoGen, Inc (NASDAQ:AXGN) Expected to Announce Earnings of -$0.14 Per Share
- Wall Street brokerages expect AxoGen, Inc (NASDAQ:AXGN) to report ($0.14) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for AxoGen’s earnings, with the highest EPS estimate coming in at ($0.07) and the lowest estimate coming in at ($0.21). AxoGen posted earnings per share of ($0.15) […]
- 03/13/2020
|
Barclays PLC Purchases 15,450 Shares of AxoGen, Inc (NASDAQ:AXGN)
- Barclays PLC increased its position in AxoGen, Inc (NASDAQ:AXGN) by 56.6% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 42,748 shares of the medical equipment provider’s stock after buying an additional 15,450 shares during the period. Barclays PLC owned about 0.11% of AxoGen worth $766,000 at […]
- 03/13/2020
|
The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 12.)
Masimo...
- 03/13/2020
|
Stocks That Hit 52-Week Lows On Thursday
|
AxoGen trading halted, volatility trading pause AXGN
- AxoGen trading halted, volatility trading pause AXGN
- 03/12/2020
|
AxoGen trading resumes AXGN
- AxoGen trading resumes AXGN
- 03/12/2020
|
The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 11)
Bicycle Therapeutics...
- 03/12/2020
|
Analysts Expect AxoGen, Inc (NASDAQ:AXGN) Will Announce Quarterly Sales of $27.05 Million
- Analysts expect AxoGen, Inc (NASDAQ:AXGN) to post sales of $27.05 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for AxoGen’s earnings, with the lowest sales estimate coming in at $26.90 million and the highest estimate coming in at $27.20 million. AxoGen posted sales of $23.29 million during […]
- 03/12/2020
|
The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 11)
Bicycle Therapeutics...
- 03/12/2020
|
Stocks That Hit 52-Week Lows On Wednesday
- During Wednesday's morning session, 690 stocks hit new 52-week lows.
Intriguing Points:
Boeing (NYSE: BA) was the biggest company on a market cap basis to set a new...
- 03/11/2020
|
The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 10) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) Aytu Bioscience Inc (NASDAQ: AYTU ) ( announced a deal to distribute COVID-19 test) Centogene NV (NASDAQ: CNTG ) Forty Seven Inc (NASDAQ: FTSV ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 10) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Akari Therapeutics PLC (NASDAQ: AKTX ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Alkermes Plc (NASDAQ: ALKS ) Allena Pharmaceuticals Inc (NASDAQ: ALNA ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) AngioDynamics, Inc. (NASDAQ: ANGO ) ANI Pharmaceuticals Inc (NASDAQ: ANIP ) Anixa Biosciences Inc (NASDAQ: ANIX ) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Aptinyx Inc (NASDAQ: APTX ) Assertio Therapeutics Inc (NASDAQ: ASRT ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Atossa Therapeutics Inc (NASDAQ: ATOS ) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) AxoGen, Inc Common Stock (NASDAQ: AXGN ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) Bausch Health Companies Inc (NYSE: BHC ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) BENITEC BIOPHAR/S ADR (NASDAQ: BNTC ) BioLife Solutions Inc (NASDAQ: BLFS ) bluebird bio Inc (NASDAQ: BLUE ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Capricor Therapeutics Inc (NASDAQ: CAPR ) Celcuity Inc (NASDAQ: CELC ) Cerecor Inc (NASDAQ: CERC ) Chembio Diagnostics Inc (NASDAQ: CEMI ) Eiger Biopharmaceuticals Inc (NASDAQ: EIGR ) Enochian Biosciences Inc (NASDAQ: ENOB ) Entasis Therapeutics Holdings Inc (NASDAQ: ETTX ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evolus Inc (NASDAQ: EOLS ) Exicure Inc (NASDAQ: XCUR ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Gossamer Bio Inc (NASDAQ: GOSS ) Gritstone Oncology Inc (NASDAQ: GRTS ) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) Heron Therapeutics Inc (NASDAQ: HRTX ) Incyte Corporation (NASDAQ: INCY ) INmune Bio Inc (NASDAQ: INMB ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) Jaguar Health Inc (NASDAQ: JAGX ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Kura Oncology Inc (NASDAQ: KURA ) Lantheus Holdings Inc (NASDAQ: LNTH ) TapImmune Inc.
- 03/11/2020
|
Bank of Montreal Can Has $3.04 Million Position in AxoGen, Inc (NASDAQ:AXGN)
- Bank of Montreal Can boosted its holdings in shares of AxoGen, Inc (NASDAQ:AXGN) by 154.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 169,735 shares of the medical equipment provider’s stock after buying an additional 103,029 shares during the […]
- 03/09/2020
|
AxoGen (NASDAQ:AXGN) Raised to "Strong-Buy" at ValuEngine
- ValuEngine upgraded shares of AxoGen (NASDAQ:AXGN) from a buy rating to a strong-buy rating in a report released on Tuesday, ValuEngine reports. A number of other equities research analysts have also weighed in on AXGN. BidaskClub raised AxoGen from a sell rating to a hold rating in a research report on Thursday, February 20th. Canaccord […]
- 03/07/2020
|
Edited Transcript of AXGN earnings conference call or presentation 24-Feb-20 9:30pm GMT
- Q4 2019 AxoGen Inc Earnings Call
- 03/06/2020
|
Visiongain Launches Report Examining the Potential in the $118bn Translational Regenerative Medicine Market
- The Global Translational Regenerative Medicine market is estimated to grow at a CAGR of 24% in the first half of the forecast period. Stem cell therapies accounted for the majority of the revenue in the market with an estimated market share of 59% in 2019.
- 03/06/2020
|
Edited Transcript of AXGN earnings conference call or presentation 24-Feb-20 9:30pm GMT
- Q4 2019 AxoGen Inc Earnings Call
- 03/04/2020
|
Axogen, Inc. to Participate at Upcoming Investor Conferences
- Axogen, Inc. (AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that members of its management team will participate in two investor conferences during March. Karen Zaderej, chairman, CEO, and president will present at the Barclays Global Healthcare Conference in Miami. Peter J. Mariani, chief financial officer, will meet with investors at the BTIG Medical Technology, Tools & Diagnostics Conference in Snowbird, UT on March 19, 2020.
- 03/02/2020
|
Axogen, Inc. to Participate at Upcoming Investor Conferences
- ALACHUA, Fla., March 02, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions...
- 03/02/2020
|
AxoGen, Inc (NASDAQ:AXGN) Sees Large Decline in Short Interest
- AxoGen, Inc (NASDAQ:AXGN) saw a large drop in short interest in February. As of February 14th, there was short interest totalling 1,500,000 shares, a drop of 9.6% from the January 30th total of 1,660,000 shares. Based on an average trading volume of 331,700 shares, the days-to-cover ratio is presently 4.5 days. Currently, 4.2% of the […]
- 03/02/2020
|
AxoGen, Inc (NASDAQ:AXGN) Expected to Earn FY2020 Earnings of ($0.69) Per Share
- AxoGen, Inc (NASDAQ:AXGN) – Cantor Fitzgerald decreased their FY2020 earnings per share (EPS) estimates for shares of AxoGen in a research note issued to investors on Wednesday, February 26th. Cantor Fitzgerald analyst C. Bijou now forecasts that the medical equipment provider will earn ($0.69) per share for the year, down from their prior forecast of […]
- 03/02/2020
|
Axogen, Inc. to Participate at Upcoming Investor Conferences
|
M&T Bank Corp Buys 2,883 Shares of AxoGen, Inc (NASDAQ:AXGN)
- M&T Bank Corp increased its stake in shares of AxoGen, Inc (NASDAQ:AXGN) by 21.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 16,123 shares of the medical equipment provider’s stock after purchasing an additional 2,883 shares during the quarter. M&T Bank Corp’s holdings in […]
- 03/01/2020
|
Q2 2020 Earnings Forecast for AxoGen, Inc (NASDAQ:AXGN) Issued By Jefferies Financial Group
- AxoGen, Inc (NASDAQ:AXGN) – Analysts at Jefferies Financial Group lowered their Q2 2020 earnings per share (EPS) estimates for shares of AxoGen in a note issued to investors on Tuesday, February 25th. Jefferies Financial Group analyst R. Denhoy now expects that the medical equipment provider will post earnings of ($0.13) per share for the quarter, […]
- 02/29/2020
|
AxoGen, Inc Expected to Post Q1 2020 Earnings of ($0.27) Per Share (NASDAQ:AXGN)
- AxoGen, Inc (NASDAQ:AXGN) – Equities researchers at Svb Leerink issued their Q1 2020 earnings per share estimates for shares of AxoGen in a research note issued to investors on Tuesday, February 25th. Svb Leerink analyst R. Newitter expects that the medical equipment provider will post earnings of ($0.27) per share for the quarter. Svb Leerink […]
- 02/28/2020
|
AxoGen, Inc. Just Reported, And Analysts Assigned A US$22.17 Price Target
- It's been a sad week for AxoGen, Inc. (NASDAQ:AXGN), who've watched their investment drop 13% to US$12.99 in the week...
- 02/27/2020
|
Organogenesis: Undervalued And Promising Investment Opportunity For 2020
- Puraply is a key growth driver of Organogenesis’ advanced wound care business. There are multiple short-term, mid-term, and long-term growth catalysts for the c
- 02/27/2020
|
95 Biggest Movers From Yesterday
|
Analysts Have Been Trimming Their AxoGen, Inc. Price Target After Its Latest Report
- It's been a mediocre week for AxoGen, Inc. (NASDAQ:AXGN) shareholders, with the stock dropping 18% to US$12.12 in the...
- 02/26/2020
|
80 Biggest Movers From Yesterday
- Gainers
Nemaura Medical Inc. (NASDAQ: NMRD) shares jumped 77.4% to close at $5.80 on Tuesday.
Cocrystal Pharma Inc (NASDAQ: COCP) shares surged 64.7% to close at $2.19 on...
- 02/26/2020
|
AxoGen (NASDAQ:AXGN) Stock Price Down 17% Following Weak Earnings
- Shares of AxoGen, Inc (NASDAQ:AXGN) were down 17% on Tuesday following a dissappointing earnings announcement. The stock traded as low as $11.80 and last traded at $12.12, approximately 926,569 shares were traded during trading. An increase of 170% from the average daily volume of 343,605 shares. The stock had previously closed at $14.60. The medical […]
- 02/26/2020
|
75 Stocks Moving In Wednesday's Mid-Day Session
|
AxoGen (AXGN) Receives a Buy from BTIG
- In a report released yesterday, Ryan Zimmerman from BTIG maintained a Buy rating on AxoGen (AXGN), with a price target of $19.00. The company's shares
- 02/25/2020
|
AxoGen (AXGN) Receives a Buy from BTIG
- In a report released yesterday, Ryan Zimmerman from BTIG maintained a Buy rating on AxoGen (AXGN – Research Report), with
- 02/25/2020
|
AxoGen (NASDAQ:AXGN) Announces Earnings Results, Misses Expectations By $0.01 EPS
- AxoGen (NASDAQ:AXGN) released its quarterly earnings data on Monday. The medical equipment provider reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.01), Bloomberg Earnings reports. AxoGen had a negative return on equity of 17.82% and a negative net margin of 26.79%. The business had revenue of $28.16 […]
- 02/25/2020
|
AxoGen's (AXGN) "Buy" Rating Reaffirmed at Canaccord Genuity
- AxoGen (NASDAQ:AXGN)‘s stock had its “buy” rating reiterated by research analysts at Canaccord Genuity in a research report issued to clients and investors on Tuesday, AnalystRatings.com reports. They presently have a $22.00 target price on the medical equipment provider’s stock. Canaccord Genuity’s price objective indicates a potential upside of 50.68% from the stock’s current price. […]
- 02/25/2020
|
Canaccord Genuity Keeps a Buy Rating on AxoGen (AXGN)
- In a report released yesterday, Kyle Rose from Canaccord Genuity reiterated a Buy rating on AxoGen (AXGN), with a price target of $22.00. The company's
- 02/25/2020
|
Canaccord Genuity Keeps a Buy Rating on AxoGen (AXGN)
- In a report released yesterday,
Kyle Rose
from Canaccord Genuity reiterated a
Buy
rating on AxoGen (
AXGN
–
Research Report
), with a price target of
$22.00
. The company’s shares closed last Monday at $14.60.
According to
TipRanks.com
, Rose is a 4-
- 02/25/2020
|
AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q4 2019 Results - Earnings Call Transcript
- AxoGen, Inc. (NASDAQ:AXGN) Q4 2019 Earnings Conference Call February 24, 2020 04:30 PM ET Company Participants Peter Mariani - Chief Financial Officer Karen Zad
- 02/25/2020
|
AxoGen Inc (AXGN) Q4 2019 Earnings Call Transcript
- AXGN earnings call for the period ending December 31, 2019.
- 02/25/2020
|
AxoGen: 4Q Earnings Snapshot
- ALACHUA, Fla. (AP) _ AxoGen Inc. (AXGN) on Monday reported a loss of $7 million in its fourth quarter. On a per-share basis, the Alachua, Florida-based company said it had a loss of 18 cents. The regenerative medicine company posted revenue of $28.2 million in the period.
- 02/24/2020
|
Axogen, Inc. Reports Fourth Quarter and Full-Year 2019 Financial Results
- ALACHUA, Fla., Feb. 24, 2020 -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today.
- 02/24/2020
|
Axogen, Inc. Reports Fourth Quarter and Full-Year 2019 Financial Results
- ALACHUA, Fla., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions...
- 02/24/2020
|
AxoGen (NASDAQ:AXGN) Stock Rating Upgraded by BidaskClub
- BidaskClub upgraded shares of AxoGen (NASDAQ:AXGN) from a sell rating to a hold rating in a report issued on Thursday, BidAskClub reports. Several other equities research analysts have also recently issued reports on the stock. ValuEngine cut shares of AxoGen from a strong-buy rating to a buy rating in a research note on Wednesday, January […]
- 02/24/2020
|
AxoGen Reaffirms FY20 Sales Guidance Of $124M-$128M vs $131.75M Est.
|
The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace
- Biotech stocks turned in a lackadaisical performance last week amid earnings releases by smid-cap stocks, a few clinical readouts and data presentations at conferences and a handful of FDA verdicts. Merck ...
- 02/23/2020
|
BerganKDV Wealth Management LLC Lowers Stock Holdings in AxoGen, Inc (NASDAQ:AXGN)
- BerganKDV Wealth Management LLC decreased its position in shares of AxoGen, Inc (NASDAQ:AXGN) by 30.3% during the fourth quarter, HoldingsChannel reports. The firm owned 23,000 shares of the medical equipment provider’s stock after selling 10,000 shares during the period. BerganKDV Wealth Management LLC’s holdings in AxoGen were worth $411,000 at the end of the most […]
- 02/23/2020
|
The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace
|
Analyzing AxoGen (NASDAQ:AXGN) and TransMedics Group (NASDAQ:TMDX)
- AxoGen (NASDAQ:AXGN) and TransMedics Group (NASDAQ:TMDX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk. Analyst Ratings This is a summary of recent ratings for AxoGen and TransMedics Group, as provided […]
- 02/22/2020
|
AxoGen (AXGN) to Release Quarterly Earnings on Monday
- AxoGen (NASDAQ:AXGN) is set to announce its earnings results after the market closes on Monday, February 24th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link. Shares of AXGN stock opened at $14.70 on […]
- 02/22/2020
|
AxoGen, Inc (NASDAQ:AXGN) Shares Acquired by Synovus Financial Corp
- Synovus Financial Corp lifted its position in shares of AxoGen, Inc (NASDAQ:AXGN) by 11.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,021 shares of the medical equipment provider’s stock after acquiring an additional 732 shares during the quarter. […]
- 02/21/2020
|
AxoGen, Inc (NASDAQ:AXGN) Expected to Announce Earnings of -$0.08 Per Share
- Equities research analysts forecast that AxoGen, Inc (NASDAQ:AXGN) will post earnings of ($0.08) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for AxoGen’s earnings. AxoGen posted earnings per share of ($0.09) in the same quarter last year, which would suggest a positive year over year growth […]
- 02/17/2020
|
Axogen, Inc. to Present at the Leerink Partners 9th Annual Global Healthcare Conference
- ALACHUA, Fla., Feb. 05, 2020 -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral.
- 02/05/2020
|
Axogen, Inc. to Present at the Leerink Partners 9th Annual Global Healthcare Conference
|
Axogen, Inc. to Report Fourth Quarter and Full-Year 2019 Financial Results and Host Conference Call on February 24, 2020
- Axogen, Inc. (AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report fourth quarter and full-year 2019 financial results on Monday, February 24, 2020 after the market closes. Axogen management will host an investment-community conference call and webcast following the release at 4:30 p.m. ET. Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795.
- 02/03/2020
|
How Many AxoGen, Inc. (NASDAQ:AXGN) Shares Did Insiders Buy, In The Last Year?
- We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
- 02/03/2020
|
Analyzing AxoGen (NASDAQ:AXGN) & TransMedics Group (NASDAQ:TMDX)
- TransMedics Group (NASDAQ:TMDX) and AxoGen (NASDAQ:AXGN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations. Institutional and Insider Ownership 67.8% of TransMedics Group shares are held by institutional investors. Comparatively, 82.7% […]
- 02/03/2020
|
Axogen, Inc. to Report Fourth Quarter and Full-Year —…–9 Financial Results and Host ...
|
What Did AxoGen, Inc.’s (NASDAQ:AXGN) CEO Take Home Last Year?
- Karen Zaderej became the CEO of AxoGen, Inc. (NASDAQ:AXGN) in 2011. First, this article will compare CEO compensation...
- 01/31/2020
|
Analysts Anticipate AxoGen, Inc (NASDAQ:AXGN) Will Announce Earnings of -$0.08 Per Share
- Wall Street brokerages expect AxoGen, Inc (NASDAQ:AXGN) to post ($0.08) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for AxoGen’s earnings. AxoGen posted earnings per share of ($0.09) in the same quarter last year, which would suggest a positive year-over-year growth rate of 11.1%. The firm is […]
- 01/28/2020
|
23 Medical Devices Stocks Moving In Thursday's Session
|
27 Medical Devices Stocks Moving In Tuesday's Session
|
BidaskClub Lowers AxoGen (NASDAQ:AXGN) to Strong Sell
- BidaskClub lowered shares of AxoGen (NASDAQ:AXGN) from a sell rating to a strong sell rating in a report released on Friday morning, BidAskClub reports. Several other brokerages also recently issued reports on AXGN. BTIG Research reiterated a buy rating and issued a $21.00 price target on shares of AxoGen in a report on Monday, December […]
- 01/14/2020
|
85 Biggest Movers From Yesterday
|
AxoGen reports preliminary Q4 and FY 2019 revenue outlook
- AxoGen (NASDAQ:AXGN) announces preliminary Q4 and FY 2019 revenue guidance.Q4 and FY revenue is expected to be at least $28.1M and $106.6M, respectively.Ended Q4 with 109 direct sales representatives
- 01/13/2020
|
AxoGen sees FY20 revenue $124M-$128M, consensus $132.38M AXGN
- AxoGen sees FY20 revenue $124M-$128M, consensus $132.38M AXGN
- 01/13/2020
|
AxoGen sees FY19 revenue at least $106.6M, consensus $107.76M AXGN
- AxoGen sees FY19 revenue at least $106.6M, consensus $107.76M AXGN
- 01/13/2020
|
AxoGen sees Q4 revenue at least $28.1M, consensus $29.22M AXGN
- AxoGen sees Q4 revenue at least $28.1M, consensus $29.22M AXGN
- 01/13/2020
|
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2019 and Provides 2020 Annual Guidance
- Axogen, Inc. (AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced preliminary unaudited fourth quarter and full-year 2019 revenue. Ended the fourth quarter with 109 direct sales representatives, including 8 former OMF sales roles that were converted to full line territory reps during the quarter.
- 01/13/2020
|
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2019 and Provides 2020 Annual Guidance
- ALACHUA, Fla., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions...
- 01/13/2020
|
Axogen Sees FY2020 Sales $124M-128M vs $132.38M Est
|
We’re Hopeful That AxoGen (NASDAQ:AXGN) Will Use Its Cash Wisely
- There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
- 01/10/2020
|
Stock Analysts' Downgrades for January, 10th (AAVVF, AAWW, ADMA, AIQUY, AMNB, AMRN, AOBC, AOIFF, ATOM, ATRI)
- Stock Analysts’ downgrades for Friday, January 10th: Advantage Oil & Gas (OTCMKTS:AAVVF) was downgraded by analysts at ValuEngine from a hold rating to a sell rating. Atlas Air Worldwide (NASDAQ:AAWW) was downgraded by analysts at BidaskClub from a hold rating to a sell rating. ADMA Biologics (NASDAQ:ADMA) was downgraded by analysts at ValuEngine from a […]
- 01/10/2020
|
Axogen Sponsored RANGER® Registry Reaches 2,000 Nerve Repair Enrollment Milestone
- Axogen, Inc. (AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that its RANGER registry enrollment has reached the milestone of 2,000 nerve injuries repaired with Avance® Nerve Graft. RANGER is the largest multi-center clinical registry in peripheral nerve repair.
- 01/08/2020
|
Axogen Sponsored RANGER Registry Reaches 2,000 Nerve Repair Enrollment Milestone
|
Axogen to Participate at AAHS ASPN ASRM 2020 Annual Meetings
- Axogen, Inc. (AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced its participation at the combined 2020 meetings of the American Association for Hand Surgery (AAHS), American Society for Peripheral Nerve (ASPN), and the American Society for Reconstructive Microsurgery (ASRM). The annual combined meetings bring together hand and reconstructive microsurgeons to learn about emerging clinical evidence and surgical techniques in a peer-to-peer setting.
- 01/02/2020
|
